Berger M - Search Results

1

IgPro20, the Polyneuropathy and Treatment with Hizentra^® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Berger M, Harbo T, Cornblath DR, Mielke O. Berger M, et al. Immunotherapy. 2018 Aug;10(11):919-933. doi: 10.2217/imt-2018-0036. Epub 2018 May 16. Immunotherapy. 2018. PMID: 29764262 Review.

2

Subcutaneous IgG in neurologic diseases.

Berger M. Berger M. Immunotherapy. 2014;6(1):71-83. doi: 10.2217/imt.13.146. Immunotherapy. 2014. PMID: 24341886 Review.

3

L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.

Berger M. Berger M. Immunotherapy. 2011 Feb;3(2):163-76. doi: 10.2217/imt.10.108. Immunotherapy. 2011. PMID: 21322757

4

Bioavailability of IgG administered by the subcutaneous route.

Berger M, Jolles S, Orange JS, Sleasman JW. Berger M, et al. J Clin Immunol. 2013 Jul;33(5):984-90. doi: 10.1007/s10875-013-9876-3. Epub 2013 Mar 1. J Clin Immunol. 2013. PMID: 23456255 Free PMC article.

5

Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Berger M, Allen JA. Berger M, et al. Muscle Nerve. 2015 Mar;51(3):315-26. doi: 10.1002/mus.24526. Epub 2015 Jan 29. Muscle Nerve. 2015. PMID: 25418426 Free PMC article. Review.

6

Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.

Berger M. Berger M. Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):532-8. doi: 10.1097/ACI.0b013e32834c22da. Curr Opin Allergy Clin Immunol. 2011. PMID: 21971330 Review.

7

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

Berger M, Rojavin M, Kiessling P, Zenker O. Berger M, et al. Clin Immunol. 2011 May;139(2):133-41. doi: 10.1016/j.clim.2011.01.006. Epub 2011 Jan 23. Clin Immunol. 2011. PMID: 21353644 Clinical Trial.

8

Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.

Berger M, Murphy E, Riley P, Bergman GE; VIRTUE Trial Investigators. Berger M, et al. South Med J. 2010 Sep;103(9):856-63. doi: 10.1097/SMJ.0b013e3181eba6ea. South Med J. 2010. PMID: 20689467 Clinical Trial.

9

Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.

Allen JA, Berger M, Querol L, Kuitwaard K, Hadden RD. Allen JA, et al. Among authors: berger m. J Peripher Nerv Syst. 2018 Jun;23(2):78-87. doi: 10.1111/jns.12262. Epub 2018 Apr 19. J Peripher Nerv Syst. 2018. PMID: 29573033 Free PMC article. Review.

10

Adverse effects of IgG therapy.

Berger M. Berger M. J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):558-66. doi: 10.1016/j.jaip.2013.09.012. Epub 2013 Oct 31. J Allergy Clin Immunol Pract. 2013. PMID: 24565701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,107 results

Search Page

Filters